Jakob Dupont Atara Biotherapeutics, Inc. (ATRA) insider trading activity

Jakob Dupont is EVP, Head of R&D of Atara Biotherapeutics, Inc.. Currently has a direct ownership of 290,794 shares of ATRA, which is worth approximately $3.34 Million. The most recent transaction as insider was on Mar 02, 2023, when has been sold 5,074 shares (Common Stock) at a price of $3.63 per share, resulting in proceeds of $18,418. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 291K

0% 3M change

0% 12M change

Total Value Held $3.34 Million

Jakob Dupont Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 02 2023	SELL Open market or private sale	$18,418 $3.63 p/Share	5,074 Reduced 1.71%	290,794 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	141,328 Added 32.33%	295,868 Common Stock
Nov 16 2022	SELL Open market or private sale	$19,495 $4.49 p/Share	4,342 Reduced 2.73%	154,540 Common Stock
Aug 16 2022	SELL Open market or private sale	$20,744 $5.03 p/Share	4,124 Reduced 2.53%	158,882 Common Stock
May 17 2022	SELL Open market or private sale	$20,604 $5.32 p/Share	3,873 Reduced 2.32%	163,006 Common Stock
Mar 01 2022	SELL Open market or private sale	$21,899 $9.86 p/Share	2,221 Reduced 1.31%	166,879 Common Stock
Mar 01 2022	BUY Grant, award, or other acquisition	-	78,506 Added 31.71%	169,100 Common Stock
Feb 10 2022	SELL Open market or private sale	$80,000 $16.0 p/Share	5,000 Reduced 5.23%	90,594 Common Stock
Feb 10 2022	BUY Exercise of conversion of derivative security	$47,900 $9.58 p/Share	5,000 Added 4.97%	95,594 Common Stock
Jan 03 2022	SELL Open market or private sale	$80,050 $16.01 p/Share	5,000 Reduced 5.23%	90,594 Common Stock
Jan 03 2022	BUY Exercise of conversion of derivative security	$47,900 $9.58 p/Share	5,000 Added 4.97%	95,594 Common Stock
Dec 01 2021	SELL Open market or private sale	$89,700 $17.94 p/Share	5,000 Reduced 5.23%	90,594 Common Stock
Dec 01 2021	BUY Exercise of conversion of derivative security	$47,900 $9.58 p/Share	5,000 Added 4.97%	95,594 Common Stock
Nov 16 2021	SELL Open market or private sale	$37,647 $17.12 p/Share	2,199 Reduced 2.37%	90,594 Common Stock
Nov 02 2021	SELL Open market or private sale	$82,050 $16.41 p/Share	5,000 Reduced 5.11%	92,793 Common Stock
Nov 02 2021	BUY Exercise of conversion of derivative security	$47,900 $9.58 p/Share	5,000 Added 4.86%	97,793 Common Stock
Aug 17 2021	SELL Open market or private sale	$26,965 $12.53 p/Share	2,152 Reduced 2.27%	92,793 Common Stock
May 18 2021	SELL Open market or private sale	$75,427 $14.55 p/Share	5,184 Reduced 5.18%	94,945 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	53,879 Added 34.98%	100,129 Common Stock

Also insider at

BCAC

Brookline Capital Acquisition Corp. Financial Services

Director

PYXS

Pyxis Oncology, Inc. Healthcare

BOLT

Bolt Biotherapeutics, Inc. Healthcare

Jakob Dupont

EVP, Head of R&D

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ATRA shares.

Notify only if

Value

Insider Trading

Get notified when an Atara Biotherapeutics, Inc. insider buys or sells ATRA shares.

Notify only if

Operation

Value

Type

News

Receive news related to Atara Biotherapeutics, Inc.

Track Activities on ATRA

Account